Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Febrile neutropenia (FN) is a frequent complication of cancer chemotherapy, which causes death in 4-21% of patients and worsens the quality of life of patients. As a simple and accurate way of identifying patients who are at risk of FN, a lymphocyte count on post-chemotherapy day 5 was suggested. To confirm the feasibility of this method and to define the incidence of FN among our own patient group, we conducted this prospective study. From September 2001 to February 2002, patients who received cytotoxic chemotherapy at Guro Hospital, Korea University, were enrolled. Blood sampling for a complete blood count was done on the starting day of chemotherapy and on day 3 and day 5 post-chemotherapy. The prospective results of the CBC were compared between the FN group and non-FN group. During the study period, 82 patients were enrolled. The male to female ratio was 52:30, and the median age was 56 years old (range: 14-78). Underlying malignancies were non-Hodgkin's lymphoma (14 patients), stomach cancer (17), breast cancer (11), NSCLC (7), hepatobiliary cancer (10), sarcoma (3), colorectal cancer (3), and others (17). The incidence of FN was 18% (15/82 patients), and ANC at the time of FN was 275 ± 327/μl. Duration of fever was 3.9 ± 3.5 days. The incidence of FN was significantly higher in patients with lymphocyte counts at day 3 ≤ 500/μl (P = 0.06), day 5 ≤ 500/μl (P = 0.023), day 3 ≤ 700/μl (P = 0.01), and day 5 ≤ 700/μl (P = 0.0001). As a result of a logistic regression test, a day-5 lymphocyte count ≤ 700/μl was identified as an independent risk factor for FN. In conclusion, a day-5 lymphocyte count <700/μl was a risk factor for FN. To strengthen our result, we are planning to validate in a larger patient group.

Original languageEnglish
Pages (from-to)263-266
Number of pages4
JournalAmerican Journal of Hematology
Volume73
Issue number4
DOIs
Publication statusPublished - 2003 Aug 1

Fingerprint

Chemotherapy-Induced Febrile Neutropenia
Lymphopenia
Febrile Neutropenia
Lymphocyte Count
Drug Therapy
Incidence
Breast Neoplasms
Neoplasms
Blood Cell Count
Korea
Neutropenia
Sarcoma
Non-Hodgkin's Lymphoma
Stomach Neoplasms

Keywords

  • Chemotherapy
  • Febrile neutropenia
  • Lymphopenia

ASJC Scopus subject areas

  • Hematology

Cite this

@article{8078d94a6e7b4119b8da47d2da089e7d,
title = "Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia",
abstract = "Febrile neutropenia (FN) is a frequent complication of cancer chemotherapy, which causes death in 4-21{\%} of patients and worsens the quality of life of patients. As a simple and accurate way of identifying patients who are at risk of FN, a lymphocyte count on post-chemotherapy day 5 was suggested. To confirm the feasibility of this method and to define the incidence of FN among our own patient group, we conducted this prospective study. From September 2001 to February 2002, patients who received cytotoxic chemotherapy at Guro Hospital, Korea University, were enrolled. Blood sampling for a complete blood count was done on the starting day of chemotherapy and on day 3 and day 5 post-chemotherapy. The prospective results of the CBC were compared between the FN group and non-FN group. During the study period, 82 patients were enrolled. The male to female ratio was 52:30, and the median age was 56 years old (range: 14-78). Underlying malignancies were non-Hodgkin's lymphoma (14 patients), stomach cancer (17), breast cancer (11), NSCLC (7), hepatobiliary cancer (10), sarcoma (3), colorectal cancer (3), and others (17). The incidence of FN was 18{\%} (15/82 patients), and ANC at the time of FN was 275 ± 327/μl. Duration of fever was 3.9 ± 3.5 days. The incidence of FN was significantly higher in patients with lymphocyte counts at day 3 ≤ 500/μl (P = 0.06), day 5 ≤ 500/μl (P = 0.023), day 3 ≤ 700/μl (P = 0.01), and day 5 ≤ 700/μl (P = 0.0001). As a result of a logistic regression test, a day-5 lymphocyte count ≤ 700/μl was identified as an independent risk factor for FN. In conclusion, a day-5 lymphocyte count <700/μl was a risk factor for FN. To strengthen our result, we are planning to validate in a larger patient group.",
keywords = "Chemotherapy, Febrile neutropenia, Lymphopenia",
author = "Choi, {Chul Won} and Sung, {Hwa Jung} and Park, {Kyong Hwa} and Yoon, {So Young} and Kim, {Seok Jin} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Kim, {Byung Soo} and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk}",
year = "2003",
month = "8",
day = "1",
doi = "10.1002/ajh.10363",
language = "English",
volume = "73",
pages = "263--266",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia

AU - Choi, Chul Won

AU - Sung, Hwa Jung

AU - Park, Kyong Hwa

AU - Yoon, So Young

AU - Kim, Seok Jin

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Kim, Byung Soo

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Febrile neutropenia (FN) is a frequent complication of cancer chemotherapy, which causes death in 4-21% of patients and worsens the quality of life of patients. As a simple and accurate way of identifying patients who are at risk of FN, a lymphocyte count on post-chemotherapy day 5 was suggested. To confirm the feasibility of this method and to define the incidence of FN among our own patient group, we conducted this prospective study. From September 2001 to February 2002, patients who received cytotoxic chemotherapy at Guro Hospital, Korea University, were enrolled. Blood sampling for a complete blood count was done on the starting day of chemotherapy and on day 3 and day 5 post-chemotherapy. The prospective results of the CBC were compared between the FN group and non-FN group. During the study period, 82 patients were enrolled. The male to female ratio was 52:30, and the median age was 56 years old (range: 14-78). Underlying malignancies were non-Hodgkin's lymphoma (14 patients), stomach cancer (17), breast cancer (11), NSCLC (7), hepatobiliary cancer (10), sarcoma (3), colorectal cancer (3), and others (17). The incidence of FN was 18% (15/82 patients), and ANC at the time of FN was 275 ± 327/μl. Duration of fever was 3.9 ± 3.5 days. The incidence of FN was significantly higher in patients with lymphocyte counts at day 3 ≤ 500/μl (P = 0.06), day 5 ≤ 500/μl (P = 0.023), day 3 ≤ 700/μl (P = 0.01), and day 5 ≤ 700/μl (P = 0.0001). As a result of a logistic regression test, a day-5 lymphocyte count ≤ 700/μl was identified as an independent risk factor for FN. In conclusion, a day-5 lymphocyte count <700/μl was a risk factor for FN. To strengthen our result, we are planning to validate in a larger patient group.

AB - Febrile neutropenia (FN) is a frequent complication of cancer chemotherapy, which causes death in 4-21% of patients and worsens the quality of life of patients. As a simple and accurate way of identifying patients who are at risk of FN, a lymphocyte count on post-chemotherapy day 5 was suggested. To confirm the feasibility of this method and to define the incidence of FN among our own patient group, we conducted this prospective study. From September 2001 to February 2002, patients who received cytotoxic chemotherapy at Guro Hospital, Korea University, were enrolled. Blood sampling for a complete blood count was done on the starting day of chemotherapy and on day 3 and day 5 post-chemotherapy. The prospective results of the CBC were compared between the FN group and non-FN group. During the study period, 82 patients were enrolled. The male to female ratio was 52:30, and the median age was 56 years old (range: 14-78). Underlying malignancies were non-Hodgkin's lymphoma (14 patients), stomach cancer (17), breast cancer (11), NSCLC (7), hepatobiliary cancer (10), sarcoma (3), colorectal cancer (3), and others (17). The incidence of FN was 18% (15/82 patients), and ANC at the time of FN was 275 ± 327/μl. Duration of fever was 3.9 ± 3.5 days. The incidence of FN was significantly higher in patients with lymphocyte counts at day 3 ≤ 500/μl (P = 0.06), day 5 ≤ 500/μl (P = 0.023), day 3 ≤ 700/μl (P = 0.01), and day 5 ≤ 700/μl (P = 0.0001). As a result of a logistic regression test, a day-5 lymphocyte count ≤ 700/μl was identified as an independent risk factor for FN. In conclusion, a day-5 lymphocyte count <700/μl was a risk factor for FN. To strengthen our result, we are planning to validate in a larger patient group.

KW - Chemotherapy

KW - Febrile neutropenia

KW - Lymphopenia

UR - http://www.scopus.com/inward/record.url?scp=0042309568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042309568&partnerID=8YFLogxK

U2 - 10.1002/ajh.10363

DO - 10.1002/ajh.10363

M3 - Article

C2 - 12879430

AN - SCOPUS:0042309568

VL - 73

SP - 263

EP - 266

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -